What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Ruxolitinib cream shows comparable efficacy to existing options, specifically vehicle cream, as evidenced by the TRuE-V trials where it significantly improved repigmentation. However, the evidence for its effectiveness compared to phototherapy is uncertain due to the lack of robust comparative data, leading to a rating of B++.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for ruxolitinib cream are uncertain and exceed NICE’s acceptable thresholds. The most likely ICER is higher than what is considered acceptable for NHS resources, leading to a B++ rating due to the need for price adjustments.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence suggests potential improvements in quality of life, particularly for individuals with black and brown skin tones, but the data is highly uncertain and lacks direct measures of HRQoL. The committee noted that existing measures may not fully capture the psychosocial burden of vitiligo, resulting in a B+ rating.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Ruxolitinib cream has a good safety profile with mostly mild adverse events reported in the TRuE-V trials. Serious adverse events were noted but not directly linked to the treatment, justifying a rating of A+.
Was the drug compared against what payers expect? — Comparator Selection
The primary comparator was vehicle cream, which is appropriate, but the lack of robust evidence comparing ruxolitinib cream to phototherapy limits the strength of the evidence. This leads to a B++ rating.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trials included a representative population of individuals aged 12 and over with non-segmental vitiligo. However, concerns about the generalizability of results to specific subgroups, particularly those with varying skin tones, lead to a rating of A.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Ruxolitinib cream is positioned as a secondary-care treatment, which may require adjustments in current care pathways. The integration is feasible but not seamless, resulting in a B+ rating.
Are the wider system costs understood? — Resource Use and Cost Implications
The economic model presented significant uncertainties regarding resource use and costs, particularly in relation to phototherapy and psychological support. This uncertainty leads to a B++ rating.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
While the evidence from the TRuE-V trials is robust, concerns about the economic model and the lack of direct HRQoL measures introduce uncertainty, justifying a B+ rating.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are significant uncertainties regarding the cost-effectiveness and broader impacts of ruxolitinib cream, particularly concerning its effects on different demographic groups. This leads to a B+ rating.
